Markets
NNVC Watch
NanoViricides
$1.33
$0.0775 6.19%
1 Min 5 Min 15 Min Hourly Daily
Assets Gross Profit Revenue Earnings
Chart Sentiment News Fundamentals About
Flint.Trades
@flint.tr...
44.2% Winrate 73.6% Avg Gain 2392.8% S&P Beat
Bought NNVC Shares
93d agoSwungBullish
up 16.23% At 1.08, Now 1.26
Flint.Trades
@flint.tr...
44.2% Winrate 73.6% Avg Gain 2392.8% S&P Beat
Bought NNVC Shares
93d agoDaytradedBullish
up 22.73% At 1.03, Now 1.26
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought NNVC Shares
274d agoSwungBullish
down -2.72% At 1.47, Exited 1.43
I believe that NanoViricides is on the verge of becoming a market leader in antiviral treatments with their NV-387 drug development. At $1.47, this st... Read More
Exited 265d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought NNVC Shares
298d agoSwungBullish
up 5.06% At 1.58, Exited 1.66
I just bought some shares of NNVC because I see huge growth potential in their advancements for nanotech treatments targeting Mpox. With the current p... Read More
Exited 291d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought NNVC Shares
318d agoInvestedBullish
down -30.43% At 1.84, Exited 1.28
NNVC is trading at $1.84 and they’re making significant progress with their nanotech platform, especially for COVID treatment. Given their advancement... Read More
Exited 227d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought NNVC Shares
324d agoInvestedBullish
down -38.25% At 2.17, Exited 1.34
The innovative treatments NNVC is developing for viral infections, including COVID, and their progress in clinical trials signal significant growth po... Read More
Exited 234d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought NNVC Shares
324d agoSwungBullish
down -9.11% At 2.09, Exited 1.9
NNVC's progress in treating viral infections, including COVID, with their clinical trials looking promising, positions it for a strong breakout in the... Read More
Exited 317d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought NNVC Shares
326d agoInvestedBullish
down -29.32% At 1.91, Exited 1.35
NNVC is developing innovative treatments for viral infections, including COVID, and is advancing through clinical trials. At $1.91, this stock seems p... Read More
Exited 235d ago
0 0
Tendies
@tendies
45.6% Winrate 185.6% Avg Gain 5722.1% S&P Beat
Bought NNVC Shares
328d agoSwungBullish
up 3.39% At 1.77, Exited 1.83
With NNVC progressing in clinical trials and their focus on challenging viral infections, the stock could see significant growth. At $1.89, it looks l... Read More
Exited 320d ago
0 0
Sign in or create an account Get notifications, save trades, and more
google logo Continue with Google Continue with Email
By continuing, you agree to our Terms and Privacy Policy.